{"id":950133,"date":"2026-04-09T07:22:26","date_gmt":"2026-04-09T11:22:26","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-present-new-preclinical-data-for-selective-smarca2-inhibitor-fhd-909-and-selective-cbp-ep300-and-arid1b-degrader-programs-at-the-2026-aacr-annual-meeting\/"},"modified":"2026-04-09T07:22:26","modified_gmt":"2026-04-09T11:22:26","slug":"foghorn-therapeutics-to-present-new-preclinical-data-for-selective-smarca2-inhibitor-fhd-909-and-selective-cbp-ep300-and-arid1b-degrader-programs-at-the-2026-aacr-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-present-new-preclinical-data-for-selective-smarca2-inhibitor-fhd-909-and-selective-cbp-ep300-and-arid1b-degrader-programs-at-the-2026-aacr-annual-meeting\/","title":{"rendered":"Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909\u00a0and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting"},"content":{"rendered":"
\n

\n New preclinical data for FHD-909 (LY4050784) reinforcing the potential for expansion opportunities in combination with an anti-PD-1 antibody in SMARCA4 (BRG1)-mutant lung cancer<\/em>\n <\/p>\n

\n Preclinical characterization of FHT-171, a selective CBP degrader with promise in ER+ breast cancer<\/em>\n <\/p>\n

\n Progress across Selective EP300 degrader in hematological malignancies and <\/em>
\n
\n Selective ARID1B degrader in ARID1A-mutant tumors<\/em>
\n \n <\/p>\n

WATERTOWN, Mass., April 09, 2026 (GLOBE NEWSWIRE) — Foghorn\u00ae<\/sup> Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that it will have multiple oral and poster presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting being held April 17-22, 2026, in San Diego, California. New preclinical data for Selective SMARCA2 inhibitor FHD-909 will be featured as part of an oral presentation and preclinical data for Selective CBP, Selective EP300, and Selective ARID1B degrader programs will be featured as poster presentations.<\/p>\n

\u201cFHD-909 is advancing in the clinic in collaboration with Lilly as the first potential selective SMARCA2 inhibitor for the treatment of SMARCA4-mutant cancers. We are excited to present new, compelling preclinical data further supporting potential expansion opportunities in combination with an anti-PD-1 antibody, as part of Dr. Bellon\u2019s oral presentation at this year\u2019s AACR,\u201d said Adrian Gottschalk, President, and Chief Executive Officer of Foghorn. \u201cPoster presentations will also highlight additional preclinical data characterizing our wholly owned Selective CBP, Selective EP300, and Selective ARID1B degrader programs. Collectively, these data underscore the differentiated profiles of our pipeline programs which may translate to improved therapeutic outcomes for difficult to treat cancers with significant unmet need.\u201d<\/p>\n

\n
\n Oral Presentation Details<\/u>
\n <\/strong>\n <\/p>\n

\n Title: Targeting chromatin regulatory proteins in hematologic malignancies<\/strong>
\n
\n Town Meeting: <\/strong>Chemistry, Hematologic Malignancies \u2013 From Molecules to Medicine \u2013 Driving Breakthroughs in Blood Cancer Treatment: A CICR-HMWG Town Hall
Session Date\/Time: <\/strong>Monday,\u00a0April\u00a020,\u00a06:30\u00a0p.m. \u2013\u00a08:30\u00a0p.m.\u00a0PDT\u00a0<\/strong>
Presenter:\u00a0<\/strong>Gromek Smolen, VP, Biology, Foghorn Therapeutics\u00a0<\/strong><\/p>\n

\n Title: Leveraging paralog relationships for targeting chromatin modulators in cancer: ARID1B and SMARCA2 (FHD-909)<\/strong>
\n
\n Session:\u00a0<\/strong>Molecular\/Cellular Biology and Genetics, Chemistry, Drug Development \u2013 Synthetic Lethality in Oncology: Progress Made, Pitfalls Encountered, and the Path Forward
Session Date\/Time: <\/strong>Tuesday, April 21, 10:15 a.m. \u2013\u202f11:45\u202fa.m.\u202fPDT
Presenter:\u00a0<\/strong>Steven Bellon, Chief Scientific Officer, Foghorn Therapeutics\u00a0<\/p>\n

\n Title: Towards new cancer medicines with degraders of chromatin regulatory proteins\u00a0<\/strong>
\n
\n Session:\u00a0<\/strong>Chemistry, Drug\u00a0Development, Experimental\u00a0and Molecular Therapeutics \u2013 Induced Proximity Pharmacology: Degraders and Beyond\u00a0
Session Date\/Time: <\/strong>Wednesday, April 22, 10:15 a.m. \u2013\u202f11:45\u202fa.m.\u202fPDT
Presenter:\u00a0<\/strong>Danette Daniels, VP, Degrader Platform, Foghorn Therapeutics<\/p>\n

\n
\n Poster Presentation Details\u00a0<\/u>
\n <\/strong>\n <\/p>\n

\n Title: Preclinical evaluation of selective and potent EP300 degraders demonstrates robust antitumor activity and favorable tolerability in hematologic malignancies<\/strong>
\n
\n Session:\u00a0<\/strong>Experimental and Molecular Therapeutics \u2013 Quantitative Pharmacology and Translational Modeling
Poster Number:\u00a0<\/strong>1828 \/ 16\u00a0<\/strong>
Session Date\/Time: <\/strong>Monday,\u00a0April\u00a020,\u00a09:00\u00a0a.m. \u2013\u00a012:00\u00a0p.m.\u00a0PDT\u00a0<\/strong>
Presenter:\u00a0<\/strong>Meiyun Lin, Senior Scientist, Pharmacology, Foghorn Therapeutics
Abstract: <\/strong>Click here<\/a><\/p>\n

\n Title:\u00a0Leveraging selective degradation of CBP and EP300 for potent anti-cancer activity<\/strong>
\n
\n Session: <\/strong>Chemistry\u202f\u2013 Targeted Protein Degradation and Induced Proximity
Poster\u00a0Number:<\/strong>\u00a05163 \/ 13
Session Date\/Time: <\/strong>Tuesday, April 21,\u00a09:00\u00a0a.m. \u2013\u00a012:00\u00a0p.m.\u00a0PDT\u00a0<\/strong>
Presenter:\u00a0<\/strong>Karolina Mizeracka, Principal Scientist, Cell Biology, Foghorn Therapeutics
Abstract: <\/strong>Click here<\/a><\/p>\n

\n Title: Identification of first-in-class selective ARID1B degraders<\/strong>
\n
\n Session: <\/strong>Experimental and Molecular Therapeutics \u2013 Proximity-Induced Drug Discovery 2
Poster Number:\u00a0<\/strong>5792 \/ 19\u00a0
Session Date\/Time: <\/strong>Tuesday,\u00a0April\u00a021,\u00a02:00\u00a0p.m. \u2013\u00a05:00\u00a0p.m.\u00a0PDT\u00a0
Presenter:\u00a0<\/strong>Madeleine Henley, Senior Scientist, Foghorn Therapeutics\u00a0
Abstract:<\/strong>Click here<\/a><\/p>\n

\n Title: Preclinical characterization of FHT-171, a first-in-class degrader targeting CREB-binding protein (CBP) in CBP-dependent solid tumors<\/strong>
\n
\n Session: <\/strong>Experimental and Molecular Therapeutics \u2013 Epigenetic Modulators 2
Poster Number: <\/strong>7075 \/ 22
Session Date\/Time: <\/strong>Wednesday, April 22 9:00 a.m. \u2013 12:00 p.m. PDT\u00a0
Presenter: <\/strong>Darshan Sappal, Director, Biology, Foghorn Therapeutics
Abstract:<\/strong>Click here<\/a><\/p>\n

Dr. Bellon\u2019s presentation and the posters will be accessible under the Science<\/u><\/a> section of the Company\u2019s website.<\/p>\n

\n About Foghorn Therapeutics<\/strong>\n <\/p>\n

Foghorn\u00ae Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control\u00ae platform, Foghorn is systematically studying, identifying, and validating potential drug targets within the chromatin regulatory system. The Company is developing multiple product candidates in oncology. Visit our website at\u00a0www.foghorntx.com<\/a>\u00a0for more information on the Company, and follow us on\u00a0X<\/a>\u00a0and\u00a0LinkedIn<\/a>.<\/p>\n

\n Forward-Looking Statements<\/strong>\n <\/p>\n

This press release contains \u201cforward-looking statements.\u201d Forward-looking statements include statements regarding the Company\u2019s ongoing Phase 1 trial of FHD-909 in SMARCA4-mutated cancers, pre-clinical product candidates, expected timing of clinical data, expected cash runway, expected timing of regulatory filings, and research efforts and other statements identified by words such as \u201ccould,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201clikely,\u201d \u201canticipates,\u201d \u201cintends,\u201d \u201cplans,\u201d \u201cseeks,\u201d \u201cbelieves,\u201d \u201cestimates,\u201d \u201cexpects,\u201d \u201ccontinues,\u201d \u201cprojects\u201d and similar references to future periods. Forward-looking statements are based on our current expectations and assumptions regarding capital market conditions, our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, actual results may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global political, economic, business, competitive, market and regulatory conditions, including risks relating to our clinical trials and other factors set forth under the heading \u201cRisk Factors\u201d in the Company\u2019s Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the Securities and Exchange Commission. Any forward-looking statement made in this press release speaks only as of the date on which it is made.<\/p>\n

\n Contact:<\/strong>\n <\/p>\n

Karin Hellsvik, Foghorn Therapeutics Inc.<\/p>\n

\n khellsvik@foghorntx.com<\/a>\n <\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

New preclinical data for FHD-909 (LY4050784) reinforcing the potential for expansion opportunities in combination with an anti-PD-1 antibody in SMARCA4 (BRG1)-mutant lung cancer Preclinical characterization of FHT-171, a selective CBP degrader with promise in ER+ breast cancer Progress across Selective EP300 degrader in hematological malignancies and Selective ARID1B degrader in ARID1A-mutant tumors WATERTOWN, Mass., April 09, 2026 (GLOBE NEWSWIRE) — Foghorn\u00ae Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that it will have multiple oral and poster presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting being held April 17-22, 2026, in San Diego, California. New preclinical data for Selective … <\/p>\n

Continue reading “Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909\u00a0and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-950133","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nFoghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909\u00a0and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-present-new-preclinical-data-for-selective-smarca2-inhibitor-fhd-909-and-selective-cbp-ep300-and-arid1b-degrader-programs-at-the-2026-aacr-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909\u00a0and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"New preclinical data for FHD-909 (LY4050784) reinforcing the potential for expansion opportunities in combination with an anti-PD-1 antibody in SMARCA4 (BRG1)-mutant lung cancer Preclinical characterization of FHT-171, a selective CBP degrader with promise in ER+ breast cancer Progress across Selective EP300 degrader in hematological malignancies and Selective ARID1B degrader in ARID1A-mutant tumors WATERTOWN, Mass., April 09, 2026 (GLOBE NEWSWIRE) — Foghorn\u00ae Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that it will have multiple oral and poster presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting being held April 17-22, 2026, in San Diego, California. New preclinical data for Selective … Continue reading "Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909\u00a0and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-present-new-preclinical-data-for-selective-smarca2-inhibitor-fhd-909-and-selective-cbp-ep300-and-arid1b-degrader-programs-at-the-2026-aacr-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-09T11:22:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NjY0MiM3NTI2NDA2IzIyMDI4NjI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-to-present-new-preclinical-data-for-selective-smarca2-inhibitor-fhd-909-and-selective-cbp-ep300-and-arid1b-degrader-programs-at-the-2026-aacr-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-to-present-new-preclinical-data-for-selective-smarca2-inhibitor-fhd-909-and-selective-cbp-ep300-and-arid1b-degrader-programs-at-the-2026-aacr-annual-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909\u00a0and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting\",\"datePublished\":\"2026-04-09T11:22:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-to-present-new-preclinical-data-for-selective-smarca2-inhibitor-fhd-909-and-selective-cbp-ep300-and-arid1b-degrader-programs-at-the-2026-aacr-annual-meeting\\\/\"},\"wordCount\":944,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-to-present-new-preclinical-data-for-selective-smarca2-inhibitor-fhd-909-and-selective-cbp-ep300-and-arid1b-degrader-programs-at-the-2026-aacr-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4NjY0MiM3NTI2NDA2IzIyMDI4NjI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-to-present-new-preclinical-data-for-selective-smarca2-inhibitor-fhd-909-and-selective-cbp-ep300-and-arid1b-degrader-programs-at-the-2026-aacr-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-to-present-new-preclinical-data-for-selective-smarca2-inhibitor-fhd-909-and-selective-cbp-ep300-and-arid1b-degrader-programs-at-the-2026-aacr-annual-meeting\\\/\",\"name\":\"Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909\u00a0and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-to-present-new-preclinical-data-for-selective-smarca2-inhibitor-fhd-909-and-selective-cbp-ep300-and-arid1b-degrader-programs-at-the-2026-aacr-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-to-present-new-preclinical-data-for-selective-smarca2-inhibitor-fhd-909-and-selective-cbp-ep300-and-arid1b-degrader-programs-at-the-2026-aacr-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4NjY0MiM3NTI2NDA2IzIyMDI4NjI=\",\"datePublished\":\"2026-04-09T11:22:26+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-to-present-new-preclinical-data-for-selective-smarca2-inhibitor-fhd-909-and-selective-cbp-ep300-and-arid1b-degrader-programs-at-the-2026-aacr-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-to-present-new-preclinical-data-for-selective-smarca2-inhibitor-fhd-909-and-selective-cbp-ep300-and-arid1b-degrader-programs-at-the-2026-aacr-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-to-present-new-preclinical-data-for-selective-smarca2-inhibitor-fhd-909-and-selective-cbp-ep300-and-arid1b-degrader-programs-at-the-2026-aacr-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4NjY0MiM3NTI2NDA2IzIyMDI4NjI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4NjY0MiM3NTI2NDA2IzIyMDI4NjI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-to-present-new-preclinical-data-for-selective-smarca2-inhibitor-fhd-909-and-selective-cbp-ep300-and-arid1b-degrader-programs-at-the-2026-aacr-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909\u00a0and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909\u00a0and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-present-new-preclinical-data-for-selective-smarca2-inhibitor-fhd-909-and-selective-cbp-ep300-and-arid1b-degrader-programs-at-the-2026-aacr-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909\u00a0and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting - Market Newsdesk","og_description":"New preclinical data for FHD-909 (LY4050784) reinforcing the potential for expansion opportunities in combination with an anti-PD-1 antibody in SMARCA4 (BRG1)-mutant lung cancer Preclinical characterization of FHT-171, a selective CBP degrader with promise in ER+ breast cancer Progress across Selective EP300 degrader in hematological malignancies and Selective ARID1B degrader in ARID1A-mutant tumors WATERTOWN, Mass., April 09, 2026 (GLOBE NEWSWIRE) — Foghorn\u00ae Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that it will have multiple oral and poster presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting being held April 17-22, 2026, in San Diego, California. New preclinical data for Selective … Continue reading \"Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909\u00a0and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-present-new-preclinical-data-for-selective-smarca2-inhibitor-fhd-909-and-selective-cbp-ep300-and-arid1b-degrader-programs-at-the-2026-aacr-annual-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-09T11:22:26+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NjY0MiM3NTI2NDA2IzIyMDI4NjI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-present-new-preclinical-data-for-selective-smarca2-inhibitor-fhd-909-and-selective-cbp-ep300-and-arid1b-degrader-programs-at-the-2026-aacr-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-present-new-preclinical-data-for-selective-smarca2-inhibitor-fhd-909-and-selective-cbp-ep300-and-arid1b-degrader-programs-at-the-2026-aacr-annual-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909\u00a0and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting","datePublished":"2026-04-09T11:22:26+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-present-new-preclinical-data-for-selective-smarca2-inhibitor-fhd-909-and-selective-cbp-ep300-and-arid1b-degrader-programs-at-the-2026-aacr-annual-meeting\/"},"wordCount":944,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-present-new-preclinical-data-for-selective-smarca2-inhibitor-fhd-909-and-selective-cbp-ep300-and-arid1b-degrader-programs-at-the-2026-aacr-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NjY0MiM3NTI2NDA2IzIyMDI4NjI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-present-new-preclinical-data-for-selective-smarca2-inhibitor-fhd-909-and-selective-cbp-ep300-and-arid1b-degrader-programs-at-the-2026-aacr-annual-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-present-new-preclinical-data-for-selective-smarca2-inhibitor-fhd-909-and-selective-cbp-ep300-and-arid1b-degrader-programs-at-the-2026-aacr-annual-meeting\/","name":"Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909\u00a0and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-present-new-preclinical-data-for-selective-smarca2-inhibitor-fhd-909-and-selective-cbp-ep300-and-arid1b-degrader-programs-at-the-2026-aacr-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-present-new-preclinical-data-for-selective-smarca2-inhibitor-fhd-909-and-selective-cbp-ep300-and-arid1b-degrader-programs-at-the-2026-aacr-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NjY0MiM3NTI2NDA2IzIyMDI4NjI=","datePublished":"2026-04-09T11:22:26+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-present-new-preclinical-data-for-selective-smarca2-inhibitor-fhd-909-and-selective-cbp-ep300-and-arid1b-degrader-programs-at-the-2026-aacr-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-present-new-preclinical-data-for-selective-smarca2-inhibitor-fhd-909-and-selective-cbp-ep300-and-arid1b-degrader-programs-at-the-2026-aacr-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-present-new-preclinical-data-for-selective-smarca2-inhibitor-fhd-909-and-selective-cbp-ep300-and-arid1b-degrader-programs-at-the-2026-aacr-annual-meeting\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NjY0MiM3NTI2NDA2IzIyMDI4NjI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NjY0MiM3NTI2NDA2IzIyMDI4NjI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-present-new-preclinical-data-for-selective-smarca2-inhibitor-fhd-909-and-selective-cbp-ep300-and-arid1b-degrader-programs-at-the-2026-aacr-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909\u00a0and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/950133","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=950133"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/950133\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=950133"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=950133"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=950133"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}